What is the status of the generic drug market for cabozantinib?

Cabozantinib is an oral, small-molecule tyrosine kinase inhibitor that is widely used to treat a variety of solid tumors such as advanced renal cancer, liver cancer, and medullary thyroid cancer. The original drug was developed by Exelixis. Due to its significant clinical effects and multi-target mechanism, this drug has attracted much attention in the global cancer treatment field. However, high prices have become a major factor limiting their widespread use, which has also given rise to the rapid development of the generic drug market.

In recent years, generic drugs of cabozantinib have been gradually launched in many countries, especially pharmaceutical manufacturers in India, Bangladesh and Laos. These countries have become important export destinations for global generic drugs due to their relatively mature regulatory systems and cost advantages for generic drugs. Take Laos United Pharmaceuticals as an example. The specifications of the generic cabozantinib produced by it are 20mg*90 tablets. The price per box is less than RMB 1,000 (depending on the exchange rate, which may fluctuate slightly), which is much lower than the price of the original drug, allowing many patients to obtain treatment at a lower cost.

In terms of efficacy, these generic versions mostly use the same active ingredients and dosage forms as the original drugs, and are produced in compliance withGMP (Good Manufacturing Practice). The efficacy is basically the same as the original drugs. Especially the versions produced in India and Bangladesh are often certified by third-party quality inspection agencies and have strong international recognition. The acceptance of this type of generic drugs in overseas markets is increasing year by year, and many clinicians also recognize their role in maintenance treatment.

It is worth noting that the introduction of these generic versions has not yet been officially approved in mainland China. Therefore, patients mostly obtain drugs through cross-border medical treatment, international drug purchasing, etc., which poses certain legal compliance risks. For patients who wish to use generic cabozantinib, it is recommended to evaluate the legality and quality assurance of drug sources under the guidance of a doctor, and pay attention to adverse drug reactions and individual differences to ensure the safety and effectiveness of treatment.

Reference:https://en.wikipedia.org/wiki/Cabozantinib